Navigation Links
Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
Date:3/7/2008

SOMERSET, N.J., March 7 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today reported its financial results for the second quarter of fiscal 2008.

The company recorded a net loss of approximately $1.7 million, or $0.04 per basic and diluted common share, for the second fiscal quarter ended Jan. 31, compared to a net loss of $1.9 million, or $0.04 per basic and diluted common share, for the second quarter of fiscal 2007. The increased research and development expenses of approximately $0.6 million and general and administrative expenses of approximately $0.4 million were offset by an increase in the company's state tax benefit of approximately $1.2 million, during the second quarter of fiscal 2008 as compared to the same quarter a year ago.

Net loss for the first half of fiscal 2008 of approximately $4.4 million, or $0.10 per basic and diluted common share, represents an increase of approximately $0.1 million, compared to the $4.3 million net loss, or $0.10 per basic and diluted common share, for the first half of fiscal 2007. The increased net loss in the first half of fiscal 2008 is comprised of increased research and development expenses of approximately $0.6 million and increased general and administrative expenses of approximately $0.7 million, which were offset by increased proceeds from the sale of state tax benefit of approximately $1.2 million versus the same period in fiscal 2007.

Cash and Liquidity

As of Jan. 31, the company had cash and cash equivalents of approximately $10.2 million, an increase of approximately $4.8 million, compared to cash and cash equivalents of approximately $5.4 million on Oct. 31, 2007. The company believes that this level of cash and cash equivalents is sufficient to support its activities through the fourth quarter of fiscal year 2009, based on the current expected level of receipts and expenditures.

"We are extremely pleased with the progress made at Alfacell during the most recent fiscal quarter," said Kuslima Shogen, Alfacell's chief executive officer. "We have made considerable progress towards the completion of our rolling NDA and we have entered into key partnerships to promote and prepare for the successful commercialization of ONCONASE(R)."

Clinical Trials Update

Alfacell has completed patient enrollment in the confirmatory Phase IIIb clinical trial for ONCONASE (ranpirnase) in patients suffering from unresectable malignant mesothelioma. The company plans to begin the required statistical analysis of the data generated by the trial after 316 evaluable events have occurred. A total of 313 evaluable events have occurred to date.

Commercial Update

In January, Alfacell entered into two new agreements for the commercialization of ONCONASE, including:

-- an exclusive license agreement with Par Pharmaceutical, Inc. for the

commercialization of ONCONASE in the U.S. by Strativa, the branded

product division of Par. As part of the agreement, Alfacell received a

cash payment of $5 million as a non-refundable up-front fee and is

eligible to receive additional cash milestones as well as royalties on

net sales.

-- a marketing and distribution agreement with BL&H Co. Ltd., for the

commercialization of ONCONASE in Korea, Taiwan and Hong Kong. Under

the agreement, Alfacell received a $0.1 million non-refundable up-front

fee and is eligible to receive additional cash milestones and 50% of

net sales in the territory.

Conference Call & Webcast

Alfacell will host a conference call and Webcast to discuss the financial results at 11 a.m. EST on Friday, March 7. To participate in the live conference call, U.S. residents may dial 1-877-407-9205, and international callers may dial 1-201-689-8054. A replay of the call will be available until March 14. To access the replay, U.S. residents may dial 1-877-660-6853, and international callers may dial 1-201-612-7415 and enter account number 286 and conference ID number 276752. A live Webcast and replay of the conference call will be available on Alfacell's Web site at http://www.alfacell.com.

About ONCONASE(R)

ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit http://www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in the outcome of the company's ongoing Phase IIIb clinical trial for its lead product, the company's ability to secure necessary approvals from regulatory agencies, uncertainties involving the ability of the company to finance research and development activities and its ongoing operations, potential challenges to or violations of patents, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

ALFACELL CORPORATION

Condensed Statements of Operations

Three-Months Ended Six-Months Ended

January 31 January 31

2008 2007 2008 2007

Revenues $- $- $- $-

Expenses:

Research and

development 2,033,500 1,472,578 3,649,291 3,042,763

General and

administrative 1,473,736 1,061,743 2,645,252 1,987,781

Total expenses 3,507,236 2,534,321 6,294,543 5,030,544

Loss from operations (3,507,236) (2,534,321) (6,294,543) (5,030,544)

Interest income, net 64,807 98,539 125,314 221,826

State tax benefit 1,755,380 510,467 1,755,380 510,467

Net loss $(1,687,049) $(1,925,315) $(4,413,849) $(4,298,251)

Net loss per share-

basic and diluted $(0.04) $(0.04) $(0.10) $(0.10)

Shares used in

computation of net

loss per share:

Basic and diluted 46,861,347 44,846,064 46,645,663 44,595,902

Balance Sheet Data:

January 31, July 31,

2008 2007

Cash and cash equivalents $10,207,924 $6,968,172

Total assets $11,194,580 $7,820,499

Current liabilities $2,163,216 $1,829,900

Accumulated deficit $(96,485,604) $(92,071,755)

Total stockholders equity $3,622,340 $5,778,480

Media Contact: Investor Contact:

David Schull or Wendy Lau Timothy Engel

Russo Partners Russo Partners

212-845-4271 212-845-4242

David.Schull@russopartnersllc.com Timothy.Engel@russopartnersllc.com

Wendy.Lau@russopartnersllc.com


'/>"/>
SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Alfacell to Present at BIO InvestorForum 2007
2. Alfacell to Host Fiscal Fourth Quarter and Year-End 2007 Financial Results Conference Call and Webcast
3. Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29
4. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
5. Alfacell to Host Fiscal Second Quarter 2008 Financial Results Conference Call and Webcast
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. QMed, Inc. Reports July Medicare SNP Enrollments
8. Phlo Affiliate Reports Expanded Coverage to Oregon Border
9. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Carrington Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Sequenom, Inc. (NASDAQ: SQNM ), ... through the development of innovative products and services, announced ... United States denied its petition to review ... Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") are not ... the Supreme Court,s Mayo Collaborative Services v. Prometheus Laboratories ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... NC (PRWEB) , ... June 24, 2016 , ... Researchers ... the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are ... to read it now. , Diagnostic biomarkers are signposts in the blood, lung ...
(Date:6/23/2016)... SILVER SPRING, Md. , June 23, 2016 ... evidence collected from the crime scene to track the criminal ... sick, and the U.S. Food and Drug Administration (FDA) uses ... Sound far-fetched? It,s not. ... whole genome sequencing to support investigations of foodborne illnesses. Put ...
Breaking Biology Technology:
(Date:6/22/2016)... On Monday, the Department of Homeland Security (DHS) issued ... the Biometric Exit Program. The Request for Information (RFI), ... that CBP intends to add biometrics to confirm when ... , in order to deter visa overstays, to ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/20/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring announced that after exhaustive ... the final acceptance by all three (3) Department ... (MAS) installed. Furthermore, Securus will have contracts for ... October, 2016. MAS distinguishes between legitimate wireless device ...
(Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
Breaking Biology News(10 mins):